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http://dx.doi.org/10.1016/j.ccell.2015.10.002SUMMARYp97 is a AAA-ATPase with multiple cellular functions, one of which is critical regulation of protein homeo-
stasis pathways. We describe the characterization of CB-5083, a potent, selective, and orally bioavailable
inhibitor of p97. Treatment of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated pro-
teins, retention of endoplasmic reticulum-associated degradation (ERAD) substrates, and generation of irre-
solvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response. In
xenograft models, CB-5083 causes modulation of key p97-related pathways, induces apoptosis, and has
antitumor activity in a broad range of both hematological and solid tumor models. Molecular determinants
of CB-5083 activity include expression of genes in the ERAD pathway, providing a potential strategy for
patient selection.INTRODUCTION
Oncogene-targeted therapies have made important contribu-
tions to the treatment of cancer (Ramos and Bentires-Alj,
2014), but resistance to these therapies is common and likely
to be a consequence of the plasticity and heterogeneity of can-
cer cell populations (Meacham and Morrison, 2013). The
concept of non-oncogene addiction has recently been used to
describe cellular processes that are not intrinsically oncogenic
but on which certain cancer cells rely for accelerated and unreg-
ulated growth (Luo et al., 2009). These non-oncogene addiction
pathways include DNA damage repair, mitosis, metabolism, im-
mune response, epigenetics, and protein homeostasis. By tar-
geting these pathways, the aim is to mitigate cancer cell growth
even when diverse oncogenic mutations are at play.Significance
Protein homeostasis pathways have become attractive targets
tein synthetic rate of these tumors and their consequent height
and survival. p97 is a key mediator of several protein homeo
target. We identified a small-molecule compound, CB-5083,
and has physicochemical properties that enable oral administr
in which proteasome inhibitors were inactive. We characterize
opment can be focused on tumor subsets more likely to show
Ca‘‘Protein homeostasis’’ refers to the balance among protein
synthesis, folding, quality control, and degradation and encom-
passes various pathways that many cancer cells are heavily
reliant upon for their growth and survival. The high protein syn-
thetic rate and rapid cell cycle of these cancer cells can make
them more dependent on the ‘‘quality control’’ provided by the
ubiquitin proteasome system (UPS), a central pathway control-
ling the degradative aspect of protein homeostasis (Van Drie,
2011). The relevance of targeting the UPS has been proven in
the clinical setting by the success of the proteasome inhibitors
in hematologic malignancies (Wustrow et al., 2013). However,
development of resistance (Ruschak et al., 2011) and lack of ac-
tivity in solid tumor settings (Milano et al., 2009; Wright, 2010)
support the need to develop inhibitors of other regulators of pro-
tein homeostasis.for treatment of certain tumor types because of the high pro-
ened dependence on degradative pathways for their growth
stasis processes and is therefore a strong potential cancer
that blocks p97 activity through ATP-competitive binding
ation. CB-5083 exhibited antitumor activity in tumor models
d molecular determinants of sensitivity so that clinical devel-
a response.
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Figure 1. CB-5083 Is a Potent Inhibitor of
p97’s D2 ATPase Domain
(A) Chemical structure of CB-5083.
(B) Dose-response curve of CB-5083 with recom-
binant WT p97, p97E305Q, and p97E578Q mutant
proteins in an NADH coupled ATPase assay. The
assay was conducted at 60 nM enzyme, 500 mM
ATP, and shown concentrations of CB-5083. R2
values were 0.98, 0.99, and 0.97 for WT, E305Q,
and E578Q, respectively.
(C) ATP competition assay of CB-5083withWT p97
with increasing ATP concentration.
(D) Crystal structure of p97-D2 showing ADP
binding site and relative position of mutations
found in resistant cells.
(E) Comparison of IC50 values of shown com-
pounds for p97 in biochemical assay using NADH-
based ATPase assay and cell viability assays using
ADP-glo.
Error bars are ±SEM. See also Figure S1 and
Tables S1 and S2.p97, also known as Valosin-containing protein, is an essential
and conserved member of the AAA family of adenosine triphos-
phatases (ATPases). Although the cellular functions associated
with p97 are diverse, including organelle membrane homotypic
fusion and sorting of endosomal cargo, it is clear that one of its
most important functions is as a key regulator of protein homeo-
stasis (Meyer et al., 2012). Through interaction with a number
of distinct cofactors, p97 mediates the extraction of proteins
destined for destruction by the UPS from organelles, chromatin,
andprotein complexes. For example, interactionwithUBXcofac-
torsmediates interactions with various E3 ligases to direct p97 to
certain protein degradation processes. p97 is a key regulator of
endoplasmic reticulum (ER)-associated degradation (ERAD),
which is the main quality control mechanism for soluble, mem-
brane-associated, glycosylated proteins as well as non-glycosy-
lated proteins as they are processed through the ER (Rabinovich
et al., 2002; Ye et al., 2001). The unfolded protein response (UPR)
is a pathway that acts both to resolve unfolded protein stress and
to trigger cell death when the buildup of such unfolded proteins
becomes irresolvable (Miura, 2014). Given thatmany cancer cells
can have a high reliance on their UPR and ERAD pathways as a
result of their high protein synthetic burden and possibly aneu-
ploidy (Deshaies, 2014; Oromendia and Amon, 2014), and that
a block in ERAD following inhibition of p97 function is likely to
lead to irresolvable proteotoxic stress, these pathways provide
a potential targetable vulnerability in cancer cells.654 Cancer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc.Recent efforts to discover small-mole-
cule inhibitors of p97 have resulted in the
identification of several classes of well-
characterized ATP-competitive and allo-
steric inhibitors (Chou et al., 2011, 2013;
Magnaghi et al., 2013). Although these
compounds have served as important
tools to understand more fully the cellular
consequences of inhibiting p97, they have
modest potency, their specificity is not
fully characterized, and they lack thedrug-like properties required for in vivo pre-clinical and clinical
development. We set out to discover a potent and specific
small-molecule inhibitor of p97 with drug-like properties to allow
the clinical evaluation of targeting this important component of
protein homeostasis as a therapeutic approach to treat cancer.
RESULTS
CB-5083 Is a Potent and Selective Inhibitor of p97
DBeQ andML240 (Chou et al., 2011, 2013) were used as starting
points to initiate extensive lead optimization efforts that led to the
identification of the compound CB-5083 with improved p97
inhibition in biochemical and cellular assays along with pharma-
ceutical properties suitable for clinical development (unpub-
lished data). CB-5083 (1-[4-(benzylamino)-5H,7H,8H-pyrano
[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide) is a
p97 ATPase activity inhibitor with a biochemical half maximal
inhibitory concentration (IC50) of 11 nM when tested at an ATP
concentration of 500 mM (Figures 1A, 1B, and S1A). Addition of
high concentrations of ATP to the biochemical assay caused an
increase in the IC50 of CB-5083, indicating competitive inhibition
of at least one of the two ATP binding sites in p97 (Figure 1C). The
first p97 AAA-ATPase domain (D1), which has a minor contribu-
tion to overall ATPase activity, is situated near the amino-terminal
domain that interacts with various cofactors. The second AAA-
ATPase domain (D2) is the main driver of ATPase activity in
biochemical reactions (Songet al., 2003). AnATPhydrolysis-defi-
cient mutant of the D1 ATPase site (E305Q) was inhibited by CB-
5083 at a similar potency as wild-type (WT) p97 with an IC50 of
15.4 nM, whereas we were unable to calculate an IC50 for the
D2 ATP hydrolysis mutant (E578Q) because of limitations in sol-
ubility above 20 mM, suggesting high selectivity of CB-5083 for
the D2 ATPase site of p97 (Figures 1B and S1B) (Dalal et al.,
2004). Interestingly, in an ATPase biochemical assay that con-
tains an ATP regeneration system, the maximum inhibition of
WT p97 was only 70.7%, whereas in an ATPase assay without
an ATP regeneration system, maximum inhibition was 95.6%,
suggesting that in the presence of ADP, the contribution to ATP
hydrolysis of the D1 ATPase site is minimal but in the CB-5083
D2-bound state with low ADP concentrations the ATP hydrolysis
of D1 is substantial (Figure S1C). Therefore, CB-5083 is charac-
terized as a D2-selective and potent inhibitor (Figure 1E).
In order to determine the selectivity of CB-5083 for the D2
domain of p97 over other ATP-using enzymes, a probe bind-
ing/mass spectrometry approach was used (Patricelli et al.,
2011). When tumor cell lysates were incubated with the bio-
tinylated ATP probe and 10 mM CB-5083, mass spectrometry
was used to identify which peptides were no longer bound by
the probe in the presence of CB-5083. The D2 ATPase site of
p97 was not bound by the probe in the presence of CB-5083,
whereas the D1 ATPase site of p97 was still efficiently bound,
further confirming theD2 selectivity and ATP competitive binding
of CB-5083 (Figure S1D). Among the 164 ATPase sites and 194
kinase sites bound by the probe in the tumor cell lysate, only
DNA-PK, mTOR, and PIK3C3 were identified to have significant
reduction of binding with 10 mMCB-5083 treatment (Figure S1D;
Table S1). Consistent with this finding, when CB-5083 was
tested in a panel of kinase biochemical assays at a dose of
5 mM, DNA-PK, mTOR, and PIK3C3 were the top hits. Subse-
quent dose titration assays revealed that CB-5083 had 29.6-,
128-, and 158-fold less affinity for DNA-PK, mTOR, and
PIK3C3, respectively, compared with p97 (Figures S1D and
S1E and Table S2). Furthermore, in a cell-based assay, CB-
5083 was shown not to inhibit DNA-PK at concentrations that
caused cell death (Figure S1F). Together these data suggest
that CB-5083 is a highly selective inhibitor for the D2 site of p97.
Generating drug-adapted cell lines that harbor resistance fol-
lowed by target gene sequencing is amethod that can be used to
determine compound specificity (Wacker et al., 2012). To identify
the cellular target of CB-5083, HCT116 colon cancer cells were
treated with increasing concentrations of CB-5083, and muta-
tion-driven, drug-resistant clones were selected. Resistant
clones demonstrated 2- to 50-fold shifts in the half maximal
growth inhibition of CB-5083 in a 72 hr viability assay (Fig-
ure S1G). p97 cDNA was isolated from these clones and
sequenced. Single homozygous coding mutations that mapped
either directly in or adjacent to the D2 ATPase domain were
found in the majority of CB-5083-resistant clones (Figures 1D
and S1H). Furthermore, when several of the identified mutations
were introduced into recombinant p97, changes in biochemical
potency of CB-5083 were similar to what was seen in mutant
cell viability. The mutant cell viability and recombinant protein
sensitivity results suggest that p97 mutations are driving cellular
resistance in the analyzed clones, further supporting on-target
specificity of CB-5083 (Figures S1I and S1J).CaCellular Effects of CB-5083
We next wanted to characterize the cellular pharmacodynamic
(PD) effects of CB-5083. Given the prominent role of p97 in
ERAD, we treated human embryonic kidney 293T cells stably ex-
pressing TCRa-GFP, a validated ERAD substrate (DeLaBarre
et al., 2006), with CB-5083. CB-5083 treatment led to a dose-
dependent accumulation of TCRa-GFP in the ER with a half
maximal effective concentration (EC50) of 0.73 ± 0.04 mM, sug-
gesting a direct block in ER extraction (Figures 2A and 2B). On
the contrary, inhibition of proteasome activity with bortezomib
led to an accumulation of TCRa-GFP in the cytoplasm and
aggresomes, suggesting that blocking protein degradation is
not sufficient to trap TCRa-GFP in the ER. To determine if CB-
5083 blocks ERAD-independent protein degradation, we evalu-
ated the stability of the cytoplasmic UPS substrate GFPu (Bence
et al., 2001). The accumulation of GFPu was observed after
CB-5083 treatment with similar potency to what was seen with
TCRa-GFP (EC50 = 1.05 ± 0.01 mM) (Figures S2A and S2B). To
monitor the impact on endogenous substrate degradation, we
measured accumulation of endogenous K48 poly-ubiquitinated
proteins visualized by immunofluorescence in the lung carci-
noma cell line A549. Accumulation of poly-ubiquitinated proteins
following CB-5083 treatment was seen initially in the cytoplasm
but then primarily in the nucleus at later time points, supporting
the notion that ERAD-independent substrate degradation is
also blocked (Figures 2C, 2D, and S2C). The predominant nu-
clear accumulation of K48 poly-ubiquitin with CB-5083 was in
contrast to bortezomib treatment that caused poly-ubiquitinated
protein accumulation primarily in the cytoplasm and aggresomes
(Figures 2C, 2D, and S2D). Consistent with a p97 role in nuclear
protein extraction (Meerang et al., 2011), A549 cells transfected
with small interfering RNA (siRNA) oligonucleotides targeting p97
that led to a reduction in p97 protein levels showed a similar
nuclear accumulation of K48 poly-ubiquitin compared with
CB-5083 treatment (Figures S2E and S2F). Additionally, K48-
ubiquitinated proteins from CB-5083-treated HCT116 cells
accumulated at a higher molecular weight compared with borte-
zomib-treated cells (Figure 2E). These data suggest that p97
inhibition has a direct role in nuclear and cytosolic protein degra-
dation in addition to its effect on ERAD.
p97 has also been shown to play a critical role in autophagy,
another major cellular pathway for protein degradation (Bug
and Meyer, 2012). To determine if CB-5083 modulated auto-
phagy, we visualized the autophagy adaptor protein p62 (also
known as sequestosome 1) (Bjørkøy et al., 2006) by immunoflu-
orescence after drug treatment in A549 cells (Figures 2C, 2F, and
S2C). Upon CB-5083 treatment, p62 was targeted to peri-nu-
clear foci, some of which co-localizedwith the K48 poly-ubiquitin
and microtubule-associated protein 1A/1B-light chain 3 (LC3)
puncta. These foci rapidly cleared from cells, a phenotype that
is consistent with the activation of autophagy, which is in contra-
diction to the previously defined role for p97 as a mediator of
autophagy. In support of the notion that CB-5083 activates
rather than inhibits autophagy, the mTOR inhibitor INK-128,
which activates autophagy (Schenone et al., 2011), also caused
a decrease in p62 levels (Figures 2F and S2G). Conversely,
the autophagy inhibitor bafilomycin A1 (Yamamoto et al., 1998)
caused an accumulation of p62 in peri-nuclear foci that co-
localized with the key autophagy regulator LC3. Additionally,ncer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc. 655
Figure 2. CB-5083 Blocks Major Cellular
Protein Degradation Functions
(A) Example images of human embryonic kidney
293 (HEK293) cells expressing TCRa-GFP with
RFP labeled ER (ER-RFP) treated with 2.5 mM CB-
5083 or 1 mM bortezomib for 6 hr. The scale bar
represents 20 mm and applies to all images.
(B) Analysis of TCRa-GFP fluorescence in cells
treated with dose titration of CB-5083 or bortezo-
mib. R2 values were 0.95 and 0.93 for bortezomib
and CB-5083, respectively.
(C) Example images of non-small-cell lung cancer
cell line A549 labeled with anti-K48-ubiquitin (K48-
Ub) and anti-p62 antibodies treated with 2.5 mM
CB-5083 or 1 mM bortezomib for 6 hr. The scale
bar represents 20 mm and applies to all images.
(D) K48-Ub and p62 were evaluated by immuno-
fluorescence in A549 cells treated with dose titra-
tion of CB-5083 or bortezomib. R2 values were
0.91 and 0.94 for bortezomib and CB-5083,
respectively.
(E) Colon cancer cell line HCT116 was treated with
CB-5083 or bortezomib for 24 hr. K48-Ub conju-
gates and p53 were analyzed by western blot.
(F) p62 modulation was evaluated by immunoflu-
orescence in A549 cells treated with CB-5083,
bortezomib, NMS-873, INK128, and bafilomycin
A1. R2 values were and 0.96, 0.93, 0.83, 0.78, and
0.86 for CB-5083, NMS-873, bafilomycin A1,
INK128, and bortezomib, respectively.
Error bars are ±SEM. See also Figure S2.bortezomib, which had previously been shown to induce auto-
phagy, and NMS-873, a structurally distinct p97 inhibitor, both
caused decreases in p62 levels. siRNA-mediated knockdown
of p97 also caused a punctate redistribution and a decrease in
the level of p62, suggesting that the observed CB-5083 effect
on this pathway is through p97 (Figures S2H). To determine if
the loss of p62 was mediated through autophagy, CB-5083
was combined with bafilomycin A1, this resulted in a block of
the p62 clearance seen with CB-5083 alone (Figure S2I). These
data indicate that autophagy is likely activated by CB-5083,
which is consistent with studies that report induction of ER stress
leads to strong autophagy activation (Ogata et al., 2006).
Accumulation of misfolded proteins in the ER and other organ-
elles can trigger the UPR (Sano and Reed, 2013). The UPR can
be activated via one of three pathways: inositol-requiring
enzyme 1, activating transcription factor 6 (ATF6), or protein ki-
nase R-like kinase (PERK). CB-5083 caused activation of all
three branches of the UPR to levels that were greater in most
cases than treatment with bortezomib and comparable with656 Cancer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc.treatment with the sarcoplasmic ER cal-
cium-ATPase inhibitor thapsigargin or
the glycosylation inhibitor tunicamycin
(Figures 3A and 3B). Induction of any
branch of the UPR can lead to the accu-
mulation of the transcription factor
CCAAT/enhancer-binding protein homol-
ogous protein (CHOP) (Wang et al., 2007;
Yoshida et al., 2000). A rapid and sus-
tained induction of CHOP protein wasseen with CB-5083 treatment of A549 cells, with an EC50 of
1.19 ± 0.23 mM (Figures 3A, 3C, S3A, and S3B).
To further investigate UPR activation, the expression levels of
genes involved in UPR and ER function were measured by RT-
PCR after cells were treated with CB-5083. Many genes were
upregulated upon CB-5083 treatment (Figure 3D; Table S3).
CHOP was the most highly upregulated gene within the RT-
PCR panel in both A549 cells and colorectal carcinoma cell
line HCT116 when treated with CB-5083. Heat shock 70 kDa
protein 5 (BiP), which is an ER-resident chaperone involved
directly in the UPR, and other genes less directly involved were
also upregulated, suggesting a strong transcriptional response
of this pathway (Table S3). Genes encoding several components
of the ERAD machinery, such as HERPUD1, SEL1L, SYVN1,
EDEM1, and HSPA5, were also among the most upregulated
genes, suggesting a potential compensatory mechanism spe-
cific to the inhibition of ERAD. To determine if CB-5083-medi-
ated induction of gene expression was specific to the UPR,
transcriptome expression analysis was conducted using RNA
Figure 3. CB-5083 Induces a Strong UPR
(A) A549 cells were treated with CB-5083, borte-
zomib (1 mM), thapsigargin (1 mM), or tunicamycin
(2 mg/ml) for 8 hr. Western blot analysis was per-
formed with antibodies against BiP, spliced XBP1
(XBP1s), PERK, phospho-EIF2a, CHOP, cleaved
(cl) ATF6, and GAPDH.
(B) A549 or HCT116 cells were treated with CB-
5083 (1 mM) or bortezomib (10 nM) for 8 hr. Relative
gene expression of spliced and unspliced XBP1
were measured by RT-PCR.
(C) A549 cells were treated with CB-5083 (2.5 mM)
or bortezomib (0.5 mM) for the indicated times, and
CHOP protein levels were quantified by immuno-
fluorescence staining.
(D) A549 or HCT116 cells were treated with CB-
5083 (1 mM) for 8 hr. Relative gene expression of a
panel of UPR genes, spliced XBP1, and unspliced
XBP1 were measured by RT-PCR.
(E) HCT116 cells were treated with CB-5083 (1 mM)
for 8 hr and processed for RNA-seq. GO enrich-
ment analysis was performed on top 500 upregu-
lated genes. The top tenmost significant GO terms
are listed.
Error bars are ±SEM. See also Figure S3 and
Table S3.sequencing (RNA-seq). Following gene ontology (GO) enrich-
ment analysis of upregulated genes, we found that the most sig-
nificant GO terms were related to UPR or ER stress (Figure 3E).
Together, these data suggest that CB-5083 causes a strong and
specific UPR response in cancer cells, which is very consistent
with a specific inhibition of its target, p97.
CB-5083 Causes Cancer Cell Death
Death receptor 5 (DR5) has recently been shown to play an
essential role in UPR-induced cell death (Lu et al., 2014). Consis-
tent with induction of the UPR, CB-5083 induced an 18.9-fold
upregulation of DR5 mRNA and a 7.7-fold upregulation of DR5
protein in HCT116 cells after 24 hr of treatment (Figures 4A
and S4A), and increases in DR5 protein were seen at time points
when increases in CHOP were observed (Figures S4A and S4B).
DR5 has been shown to activate caspase-8 as a means of initi-
ating the apoptosis cascade (Lu et al., 2014). Upon CB-5083
treatment in A549 and HCT116 cells, induction of caspase-8Cancer Cell 28, 653–665,and caspase-3/7 coincided with upregu-
lation of DR5 (Figures 4B and 4C). Viability
in both of these cell lines also began to
decrease with a timing that was coinci-
dent with DR5 induction and caspase
activation (Figure 4D). Potencies of cell
death were similar to potencies of K48
poly-ubiquitin and CHOP protein accu-
mulation, suggesting that the buildup of
proteins marked for degradation and in-
duction of the UPR may be linked to cell
death (Figures 2D, S3B, and S4C).
To determine if CHOP pathway induc-
tion was driving cellular cytotoxicity,
HCT116 cells were treated with CB-5083after siRNA-mediated knockdown of BiP, PERK, CHOP, DR5,
or caspase-8 (Figure 4E). Knockdown of BiP, which is a chap-
erone protein that acts in protective mechanisms of the UPR
(Morris et al., 1997), did not block the decrease in viability seen
with CB-5083 treatment. siRNA-mediated knockdown of
CHOP, but not PERK, blocked CB-5083-mediated cell death,
suggesting that not all UPRpathwaysmediate CB-5083-induced
cell death. Knockdown of DR5 and caspase-8, which act down-
stream of CHOP to mediate apoptosis, also caused a block in
CB-5083-induced cell death. Similar effects were seen in A549
cellswhenDR5andcaspase-8were knockeddown (FigureS4D).
Furthermore, when cells were treated with siRNA oligos target-
ing DR5, DR5 protein induction upon CB-5083 treatment was
strongly reduced (Figure S4A). When CB-5083 was combined
with the CDK inhibitor dinaciclib, which inhibits the induction
of CHOP (Nguyen and Grant, 2014), antagonism of cellular
cytotoxicity was observed (Figure S4E). Together these data
strongly support the conclusion that CHOP-mediated apoptosisNovember 9, 2015 ª2015 Elsevier Inc. 657
Figure 4. Induction of UPR by CB-5083
Causes Cancer Cell Death
(A) A549 cells were treated with CB-5083 (1 mM) for
the indicated times. Relative DR5 gene expression
was measured by RT-PCR.
(B–D) A549 or HCT116 cells were treated with CB-
5083 (5 mM) for up to 72 hr. Caspase-8 activity (B),
caspase-3/7 activity (C), and cell count (D) were
measured at indicated times.
(E) BiP, PERK, CHOP, DR5, and caspase-8 were
knocked down in HCT116 cells for 24 hr. Cells were
then treated with CB-5083 (2.5 mM) for 24 hr, and cell
viability was measured by cell titer glo.
Error bars are ±SEM. See also Figure S4.is an important mechanism of CB-5083-induced cellular
cytotoxicity.
CB-5083 Induces the UPR and Apoptosis in Xenograft
Tumor Models
To evaluate its pharmacokinetic (PK) and PD activity, CB-5083
was administered at escalating dose levels to female nude
mice bearing HCT116 xenograft tumors. Following a single oral
dose of CB-5083, there was a dose-dependent increase in
area under the plasma concentration versus time curve (Fig-
ure 5A). Accumulation of poly-ubiquitin and CHOP in tumor tis-
sue was observed in a dose-dependent manner (Figures 5B
and 5C). Increases in DR5 protein were also seen (Figure S5A).
Additionally, p62 protein levels decreased by 60% at 6 hr at
the 100 mg/kg dose level, consistent with what was observed
in vitro (Figure 5D). To determine if markers of apoptosis were
activated in CB-5083-treated xenograft models, the levels of
cleaved poly ADP ribose polymerase (PARP) were monitored.
Increases in cleaved PARP were observed in a dose-dependent
manner with timing that was consistent with the induction
of CHOP (Figure 5E). These data demonstrate that CB-5083
achieved plasma concentrations that were sufficient to elicit a
PD as well as an apoptotic response in tumors.658 Cancer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc.CB-5083 Has Antitumor Activity in
Xenograft Tumor Models
Given the strong UPR and apoptotic
response seen with CB-5083 treatment in
animal models, the antitumor activity of
CB-5083 was assessed in nude or SCID-
Beige mice bearing established human
tumor xenografts derived from tumor
cell lines of different histologic origins:
HCT116 derived from colorectal adenocar-
cinoma, NCI-H1838 derived from non-
small-cell lung cancer, AMO-1 derived
from a plasmacytoma, and two colorectal
cancer patient-derived xenograft (PDX)
models (Figures 5F and 5G). CB-5083
was administered by oral gavage once
(qd) or twice (bid) daily or following a
4 days on, 3 days off (qd4/3off) cycle.
Inhibition of tumor growth (% TGI) was
calculated on the last day of treatment. All
CB-5083 dosing schedules tested weretolerated in tumor-bearing mice, generally resulting in weight
loss of <10% (Figures S5B–S5D). The qd4/3off schedule offered
the best therapeutic index, with significant (78%, p < 0.0001) TGI
of HCT116 tumor observed at 100mg/kg (Figure 5F). In contrast,
a 25 mg/kg bid dose induced 54% TGI (p < 0.0001), and a
50 mg/kg qd dose resulted in 62% TGI (p < 0.0001). These re-
sults were consistent with the PK and PD results, where
100 mg/kg clearly induced the highest level of apoptosis after
a single administration (Figures 5A–5E), and support the notion
of dose-dependent antitumor activity. To confirm that the anti-
tumor effects with CB-5083 in the HCT116 xenograft model
were due to inhibition of p97, the resistant HCT116 cell line
model harboring the T688A p97 mutation, which causes strong
biochemical and cellular resistance to CB-5083, was tested. Tu-
mor growth of this mutant model was not inhibited when dosed
with CB-5083 at 90mg/kg (Figure S5E). Strong antitumor activity
was seen with the qd4/3off schedule in NCI-H1838 xenografts
and the colorectal carcinoma PDX models. AMO-1 was the
most sensitive cell line identified among 350 cell lines that
were tested in vitro (IC50 = 81 nM; see below) and gave the
most striking result in xenograft growth inhibition, with complete
regressions of tumors observed in 6 of 12 animals after two cy-
cles of treatment (Figure 5G). The activity seen in the AMO1
Figure 5. CB-5083 Has Activity in Mouse Models
(A) Tumor (open box) and plasma (open circle) concentrations of CB-5083 in tumor tissue extracts from nude mice bearing HCT116 tumors after treatment at
25 and 100 mg/kg.
(B–E) Levels of poly-ubiquitin (B), CHOP (C), p62 (D), and cleaved PARP (E) were measured in tumor tissue extracts from nude mice bearing HCT116 tumors after
treatment at 25 and 100 mg/kg of CB-5083.
(F) Tumor growth was measured for various CB-5083 dosing schedules in the HCT116 xenograft model (n = 7–10).
(G) Tumor growth was measured with dosing of CB-5083 in NCI-H1838 (n = 16), AMO-1 (n = 12), CTG-0360 (n = 4), and CTG-0081 (n = 4) xenograft models.
Error bars are ±SEM. See also Figure S5.xenograft, a model derived from multiple myeloma, is consistent
with the high sensitivity seen in this indication for other protein
homeostasis pathway inhibitors such as bortezomib (Hideshima
et al., 2001). These results demonstrate that oral treatment
with CB-5083 inhibits the growth of human tumor xenografts in
mice.CaCB-5083 Is More Effective in Solid Tumor Models Than
Proteasome Inhibitors
To understand further the antitumor effect of CB-5083 and the
advantage of targeting protein homeostasis via inhibition of
p97, comparative studies with proteasome inhibitors were con-
ducted in solid tumor xenograft models. Proteasome inhibitorsncer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc. 659
Figure 6. CB-5083 Demonstrates Greater
Activity Than Proteasome Inhibitors in Solid
Tumor Models
(A) Relative levels of poly-ubiquitin measured in
HCT116 or A549 xenografts in mice administered
CB-5083 or proteasome inhibitors (n = 3 per time
point).
(B) Relative levels of CHOP measured in HCT116
xenografts in (A).
(C) Tumor growth was measured with dosing of
CB-5083 or proteasome inhibitors in HCT116 (n =
8–12) and A549 (n = 10–12) xenograft models.
Error bars are ±SEM. See also Figure S6.are approved for the treatment of multiple myeloma (bortezomib
and carfilzomib) and mantle cell lymphoma (bortezomib) but
have failed to show sustainable activity in solid tumors (Milano
et al., 2009; Wright, 2010). We compared the PD activity of
CB-5083, bortezomib, carfilzomib, and ixazomib in female
nude mice bearing HCT116 or A549 tumors. All agents were
dosed at their optimal dosing route and published active dose
in hematological models (Kupperman et al., 2010; Teicher
et al., 1999; Zhang et al., 2013) and were generally well tolerated
after repeat dosing (Figure S6). After a single administration of
CB-5083, a strong and sustained induction of poly-ubiquitin
was observed in tumor tissue, suggesting inhibition of the protein
homeostasis pathway (Figure 6A). Additionally, a clear CHOP
protein accumulation 6 hr after dosing was seen with CB-5083
(Figure 6B), suggesting UPR activation in these tumors. In
contrast to CB-5083, none of the proteasome inhibitors were
able to show significant, sustained accumulation of poly-ubiqui-
tin or CHOP. The clear difference seen in the PD experiment was
confirmed by evaluating tumor growth inhibition. CB-5083660 Cancer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc.showed a significant antitumor response
in HCT116 xenografts (Figure 6C; TGI =
63%, p < 0.0001), whereas none of the
proteasome inhibitors were active in this
model. In A549 (Figure 6C), CB-5083
was the most potent agent, with 85%
TGI (p < 0.001). In this model, carfilzomib
(TGI = 50%, p < 0.0001) and bortezomib
(TGI = 37%, p < 0.0001) showed modest
activity, whereas ixazomib was inactive
(TGI = 19%, p = 0.0285). Together these
data demonstrate that targeting p97
may be a more effective strategy for in-




Given the variability in potency seen both
in cell culture and in animals, we wanted
to determine the molecular determinants
of CB-5083 sensitivity or resistance.
Potency of cell death induction was
measured in 350 cancer cell lines repre-
senting a variety of tumor histologies (Fig-ure 7A). The range in sensitivity to CB-5083 was narrow in this
cell line panel, with EC50 values ranging from 81 nM to 2.1 mM,
possibly owing to the pleiotropic cellular functions of p97. A
good correlation was seen between EC50 and TGI for cell lines
in which antitumor activity had been measured in vivo (R2 =
0.51), suggesting that molecular determinants that drive sensi-
tivity to CB-5083 may translate from cell culture to xenograft
models (Figure 7B). Genomic data for the cell line panel were ob-
tained from the Cancer Cell Line Encyclopedia (CCLE) (Barretina
et al., 2012) and analyzed to determine which molecular and
gene expression alterations correlated with CB-5083 sensitivity.
Using linear regression, gene expression and copy number infor-
mation from CCLE was compared with CB-5083 sensitivity.
Ninety-three genes by mRNA expression and 94 gene loci by
copy number were identified to correlate significantly with either
CB-5083 sensitivity or resistance, as determined by the false
discovery method (Benjamini and Yekutieli, 2001). To further
validate the significance of gene correlates with CB-5083 sensi-
tivity, drug sensitivity was randomized prior to linear regression,
Figure 7. Activation of MAPK Pathway Cor-
relates with Sensitivity to CB-5083 in Can-
cer Cells
(A) Three hundred forty cancer cell lines were
treated with a dose titration of CB-5083, and EC50
of cell viability was measured at 72 hr. Cell lines
are ordered by EC50.
(B) TGI of a panel of cell lines in subcutaneous
xenografts after oral administration of 100 mg/kg
CB-5083 on a qd4/3off schedule for 3–4 weeks
was compared with EC50 of the same cell lines
grown in culture in a 72 hr viability assay.
(C) p97 gene copy number as measured by hybrid
capture was plotted against CB-5083 EC50 of
viability in a panel of cancer cell lines. Statistical
significance of fit to linear regression was calcu-
lated with an F test (p value).
(D) p97 mRNA level as measured by microarray
was plotted against CB-5083 EC50 of viability in a
panel of cancer cell lines. Statistical significance
of fit to linear regression was calculated with an F
test (p value).
(E) Viability in A549 cells stably expressing induc-
ible control shRNA or shRNA targeting p97 after
3 days of 500 mM IPTG treatment to induce the
expression of shRNAs followed by 3 days of CB-
5083 treatment. EC50 values were compared with
p97 protein levels as measured by western blot.
(F) CB-5083 EC50 of viability in cell lines contain-
ing an oncogenic mutation in KRAS, NRAS,
HRAS, BRAF, or NF1 were compared with cells
that were WT for all of these genes.
(G) CB-5083 EC50 values of viability in cell lines
with high or low levels of phosphorylated ERK1
and ERK2 were compared.
(H) TGI for a set of cell lines grown as xenografts
was plotted against the ratio of phosphorylated
ERK1+ ERK2 to total ERK1+ ERK2 as measured
by western blot.
See also Figure S7.resulting in a strong decrease in the significance of the gene cor-
relates, which further supports that the un-randomized gene cor-
relates are biologically significant (Figure S7A).
Both gene copy number and mRNA level of p97 correlated
with resistance to CB-5083 treatment with statistical signifi-
cance, but given the low Pearson correlation (r) values, it is clear
that other determinants of sensitivity exist across the diverse cell
panel (Figures 7C and 7D). To determine if p97 levels specify
sensitivity to CB-5083, we cloned individual p97-targeted single
guide RNAs within the CRISPRi and CRISPRa platform in K562
leukemia cells (Gilbert et al., 2014) and quantified their effect
on p97 expression by quantitative PCR (qPCR). Changes in the
p97 mRNA level were moderate, likely because of the high basal
expression of this abundant protein. We then determined the ef-
fect of p97 mRNA expression levels on CB-5083 sensitivity in a
competitive growth assay and found an excellent correlation,
with a Pearson correlation (R2) of 0.97 (Figures S7B–S7D). Addi-
tionally, when p97 was knocked down in HCT116 cells using a
stable inducible small hairpin RNA (shRNA) system resulting in
a strong reduction in protein, CB-5083 EC50 shifted on average
from 0.48 mM in the uninduced cells to 0.09 mM in the induced
cells (Figures 7E and S7E–S7H). Together, the connection be-
tween p97 mRNA and protein expression and drug sensitivityCafurther supports the notion of on-target antitumor activity of
CB-5083.
High gene expression of DR5 was among the top correlates
with CB-5083 sensitivity (Figure S7I), which is consistent with
the UPR-cell death pathway being critical for CB-5083-mediated
cell death. High expression of two genes involved in ERAD were
also identified as correlating with CB-5083 sensitivity: autocrine
motility factor receptor (AMFR/gp78), which is an E3 that directly
associates with p97 (Song et al., 2005), and enhancing a-manno-
sidase-like protein (EDEM1), which recognizes misfolded pro-
teins and is tethered to p97 through the Derlins (Oda et al.,
2006) (Figure S7I). Together these data suggest that cells with
elevated ERAD and UPR activity may be more susceptible to
p97 inhibition.
When gene mutations were compared with CB-5083 sensi-
tivity, KRAS and BRAF were among the top correlating mutant
genes. Given the role of the mitogen-activated protein kinase
(MAPK) pathway in stimulating protein synthesis (Dasgupta
et al., 2005), activating mutations in this pathway may cause
an increased dependency on the UPS. When cell lines with any
mutation in genes associated with driving MAPK activation
were compared with WT cells, there was also a correlation
between activating mutations and sensitivity to CB-5083ncer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc. 661
(Figure 7F). To look at downstream activation of the MAPK
pathway, phosphorylation of extracellular-signal-regulated ki-
nases 1 and 2 (ERK1/2) was monitored. Samples with high levels
of phospho-ERK1/2 weremore sensitive to CB-5083, both in cell
culture and xenograft models (Figures 7G, 7H, and S7L).
Together these data suggest that cancer cells with activation
of the MAPK pathway may rely heavily on p97’s function in pro-
tein homeostasis and thus be more sensitive to an inhibitor of
p97 such as CB-5083.
DISCUSSION
There is growing evidence that p97 is an important regulator of
proteotoxic stress and protein homeostasis; thus, inhibition of
p97 function provides an opportunity to target a key vulnerability
of cancer (Deshaies, 2014). We have described the activity of
a p97 small-molecule inhibitor with drug-like properties. CB-
5083 is a potent p97 inhibitor that exhibits strong selectivity
against other ATPases and kinases. Although no detectable inhi-
bition of other ATPases and only minor inhibition of several ki-
nases was observed, it remains possible that CB-5083 could
target additional ATPases that may have not been captured by
our mass spectrometry approach or biochemical screening.
However, there is clear evidence that if this were the case, it
does not contribute strongly to cellular cytotoxicity seen with
CB-5083. When resistant mutant cell lines were generated
against CB-5083, amino acid mutations within the D2 ATPase
region of p97 were identified and recapitulated in recombinant
protein, leading to 50-fold shifts in cell EC50. Together these
data give us confidence that the vast majority of cellular pheno-
types and cytotoxicity induced by CB-5083 are driven through
p97 inhibition.
Inhibition of p97 through CB-5083 was shown to have a pro-
found effect on the UPR, activating all three arms of this
conserved stress response pathway. It is intriguing that the
extent of UPR activation induced by CB-5083 was markedly
higher than that induced by the proteasome inhibitor bortezo-
mib. Consistent with a recent study that characterized the
sequential degradative pathway for a specific ERAD substrate
(Morris et al., 2014), bortezomib treatment appeared to allow
for the exit of TCRa from the ER,whichmay be the cause of lower
UPR induction compared with p97 inhibition, where protein
substrates are trapped in the ER following CB-5083 treatment.
Alternatively, the differential induction of the UPR by CB-5083
and bortezomib may be due to the different subset of proteins
whose degradation is blocked by these key regulators of protein
homeostasis.
Our data suggest that the primary mechanism of cell death for
CB-5083 appeared to be mediated through irresolvable proteo-
toxic stress. CHOP andDR5 induction caused byCB-5083 treat-
ment was required for early induction of caspase activity and
cellular cytotoxicity. At later time points, cells do eventually die
with CHOP or DR5 depletion (data not shown), suggesting that
there are other mechanisms of cellular cytotoxicity when p97 is
inhibited or that knockdown is not complete. This is not surpris-
ing given the numerous cellular functions assigned to p97.
Consistent with this notion, Eeyarestatin I, a p97-interacting
molecule that also binds directly to ER membranes, induces
cell death through ATF3, ATF4, and Noxa (Wang et al., 2009,662 Cancer Cell 28, 653–665, November 9, 2015 ª2015 Elsevier Inc.2010). These alternative routes of cell death observed may be
due to the different mode of binding between CB-5083 and
Eeyarestatin I or to different cellular systems used in these
studies.
Interestingly, it appeared as though not all cellular functions of
p97 were inhibited by CB-5083. For example, we did not see
disruption of Golgi or ER morphology at active concentrations
of CB-5083 (data not shown), suggesting that the membrane ho-
motypic fusion function of p97 may not be blocked. Additionally,
p97 has been widely reported to be required for the process of
autophagy (Ju et al., 2009; Meyer et al., 2012). Themarked clear-
ance of p62 suggests that autophagy is not inhibited with CB-
5083 treatment. Possibilities that could explain the lack of activ-
ity of CB-5083 on certain p97 functions are its specificity for the
D2 ATPase domain of p97 or that it binds preferentially to a spe-
cific p97-containing cofactor complex. Recent work reported
differential activity of p97 inhibitors on D1 and D2 sites as well
as shifts in potency in the presence of the p47 cofactor (Fang
et al., 2015). It will be interesting to interrogate the specific
cofactor interactions of CB-5083-bound p97 and how these
might relate to certain cellular functions. The role of autophagy
as a compensatory mechanism to evade the effects of a p97
inhibitor remains unclear, although other approved anti-cancer
agents appear to induce autophagy to a similar extent.
Several small-molecule inhibitors of p97 have been described
in the literature (Chou et al., 2011, 2013; Magnaghi et al., 2013),
but none has demonstrated in vivo activity. CB-5083 has demon-
strated drug-like pharmaceutical properties and modulates
UPS, UPR, and autophagy pathway markers in animal models
with magnitudes and timings that are similar to what was seen
in cell culture experiments, suggesting that inhibition of p97
leads to the same phenotypes in vivo as it does in vitro. CB-
5083 also has strong antitumor activity in hematological and
solid tumor models. CB-5083 was less active in HCT116 tumors
harboring a resistant p97 point mutation, suggesting that the
efficacy seen in other models is a result of on-target activity.
The activity seen in solid tumor models treated with CB-5083
may have profound implications for targeting protein homeosta-
sis beyond hematological disorders, which has been difficult
to achieve in the clinic with proteasome inhibitors (Johnson,
2015). Higher UPR induction seen with p97 inhibition in vivo
combined with oral administration allowing sustained exposure
of drug in the plasma may also contribute to greater solid tumor
activity compared with proteasome inhibitors and may provide
an opportunity to identify patients more likely to respond to
CB-5083 (see below).
Given the potential role of p97 in normal cells, it will be impor-
tant to establish the molecular determinants of tumor cell sensi-
tivity to CB-5083 in order to better identify patients that might
have a clinical response at dose levels that are also well toler-
ated. By screening a large panel of cancer cell lines, we were
able to identify statistically significant genomic features that
correlate with either CB-5083 sensitivity or resistance. The iden-
tification of high p97 copy number and expression levels as
genomic features that correlate with resistance to CB-5083 is
intriguing. These data further validated p97 as the cellular target
of CB-5083 and suggest that elevated levels of p97 may be a
viable exclusion criterion in the clinic. However, p97 expression
level has been reported to correlate with poor prognosis (Fessart
et al., 2013), suggesting that high expression of p97 may drive
cancer progression. p97 appears to fall in the category of drug
targets where expression of a target correlates with resistance
to a given inhibitor, such as the classical example of DHFR
amplification in methotrexate-resistant cells (Cillo et al., 1987),
rather than correlating with sensitivity, such as was recently re-
ported for the mitochondrial protein degradation enzyme ClpP
(Cole et al., 2015).
The correlation of high expression of UPR- and ERAD-related
genes with sensitivity to CB-5083 further supports the role of the
UPR as the primary driver of cellular cytotoxicity. We hypothe-
size that cancer cells with a high basal burden on their ERAD
and UPR pathways are more likely to allow CB-5083 to tip the
balance toward irresolvable proteotoxic stress and that elevated
basal levels of genes such as DR5 may be indicators of greater
susceptibility to proteotoxic stress-induced death. The correla-
tion of MAPK pathway activation and CB-5083 sensitivity was
less expected, although it also makes sense that pathways
activating protein synthesis would rely more heavily on protein
degradation to maintain protein homeostasis. One downstream
effect of having an activated MAPK pathway is increased protein
synthesis (Dasgupta et al., 2005). Another mechanism that can
drive increased protein synthesis is the activation of eIF4E by
ERK (Flynn et al., 1997). Given this hypothesis, CB-5083 may
be active in a diverse collection of MAPK activation settings,
whereas specific targeted agents such as vemurafenib (Bucheit
and Davies, 2014) are active only in settings in which the specific
target is mutated. Furthermore, CB-5083may be active as a sec-
ond line therapy in those patients who become resistant to such
targeted agents or even in combination to increase durability of
responses.
Given the above, CB-5083 was progressed through pre-clin-
ical development and is currently being evaluated in two phase
1 clinical trials, in patients with relapsed and refractory multiple
myeloma and in patients with advanced solid tumors.
EXPERIMENTAL PROCEDURES
Biochemical Assays
WTandmutant p97 proteins were expressed in BL21 (DE3) E. coli cells utilizing
the pD441-NH vector with a T5 inducible promoter (DNA2.0), as a His-tagged
protein and purified by fast protein liquid chromatography (FPLC) His-Trap col-
umn chromatography. The hexameric p97 complex was further separated by
FPLC S200 size-exclusion chromatography. CB-5083 IC50 analyses for p97
and mutants were conducted using a standard NADH-based coupled kinetic
ATPase assay and the ADP glo assay (Promega). See the Supplemental Infor-
mation for assay details.
Cell Assays
TCRa andGFPu cell lineswere a kindgift fromRonKopito (StanfordUniversity).
Cancer cell lines were obtained from American Type Culture Collection and
cultured according to the supplier’s instructions. Immunofluorescence and
western blotting assay were conducted using standard procedures. For
qPCR assays, RNA was extracted from cell lysates, and cDNA was prepared.
Transcript levels were measured by qPCR using a UPR PCR array
(SABiosciences) or Taqman primers in the QuantStudio 6 Flex PCR system
(Life Technologies). See the Supplemental Information for further assay details.
Animal Studies
The animal research conducted for this study was reviewed and approved by
the Institutional Animal Care and Use Committee of Cleave Biosciences. All
mice were treated in accordance with guidelines outlined by the Institute forCaLaboratory Animal Research Guide for the Care and Use of Laboratory Ani-
mals. Female athymic nude mice and SCID-Beige mice, 5–8 weeks of age
andweighing approximately 20–25 g, were purchased fromCharles River Lab-
oratories. Details about animal husbandry can be found in the Supplemental
Information. Cancer cell line xenografts were established by implanting 5 3
106 to 10 3 106 cells subcutaneously. CB-5083, MLN9708, and the CB-
5083 vehicle (0.5% methyl cellulose in water) were administered by oral
gavage and bortezomib and carfilzomib by tail vein injection. Tumor volume
and body weights were measured twice weekly and daily, respectively,
throughout the study.
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